Participated · Series A · Nov 2024

C Ray Therapeutics focuses on discovery, development, and manufacturing of radiopharmaceuticals including targeted Radionuclide Drug Conjugates (RDCs) and alpha-emitting therapies. The company operates a nearly 30,000 square meter R&D and production base and holds the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise. Its platform includes 13 cGMP-standard radiopharmaceutical production workshops, permits to handle over 30 medical isotopes, and automated production lines compliant with FDA, NMPA, and EMA standards. C Ray offers one-stop customized services spanning molecular imaging CRO work, companion diagnostics, target validation, and full CRDMO services from discovery through IND filing and commercial supply. The company plans to use the new financing to improve core technology platforms (including targeted ligand discovery), upgrade high-throughput screening for innovative RDCs, and accelerate clinical development of multiple pipelines—especially alpha-emitting RDC drugs. C Ray is also progressing IIT/clinical trials and overseas business development while aiming to scale its global service and commercialization capabilities.

Participated · Series B · Mar 2023

Allorion Therapeutics is a clinical-stage biotech developing precision medicines for oncology and autoimmune diseases. Its core capabilities include an allosteric inhibitor screening platform and a platform for discovery of synthetic lethality targets and molecules. The company has advanced two small molecules to IND: ARTS-011, an allosteric TYK2 pseudokinase inhibitor with an IND filed in China for autoimmune diseases, and ARTS-021, a CDK2 isoform-selective inhibitor for solid tumors with INDs to be filed in the U.S. and China. Allorion intends to use its new funding to advance upcoming Phase I/II clinical trials in both China and the U.S., identify additional clinical candidates, and further build clinical development and business development teams. Led by CEO Peter Ding, the company has 53 full-time employees across China and the U.S., including 15 executive team members with extensive pharma/biotech experience. Since its July 2020 founding the company has raised over $100M, most recently a $50M Series B. Allorion Therapeutics is a Boston, MA-based next-generation precision medicine company focused on oncology and autoimmune diseases. The company leverages a drug discovery engine that integrates breakthroughs in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors. It has built a synthetic lethality screening platform to expand targeted therapy options for cancer patients. Allorion is developing two drug candidates with plans for IND-enabling studies and IND applications in China and the United States. It intends to increase investment in its platform technologies for systematic screens for allosteric inhibitors and synthetic lethality targets with matching tool compounds. The company also plans to enhance its clinical and business development teams and recently completed a $40M Series A financing.

Participated · Equity · Oct 2019

Verseau Therapeutics is a biotechnology company creating first-in-class macrophage checkpoint modulators to treat cancer and immune/inflammatory diseases. The company focuses on therapies that reprogram macrophages to shift tumors from an immunosuppressive to a pro-inflammatory state. Verseau’s lead program targets PSGL-1 and is designed to reprogram tumor-associated macrophages, activate T cells, and recruit other immune cells to generate an antitumor response. The company licensed an siRNA lipid-nanoparticle delivery technology from the MIT labs of co-founders Dan Anderson and Bob Langer and uses an all‑human translational platform to discover and validate targets. Verseau has validated more than two dozen targets amenable to multiple modalities, including monoclonal antibodies, and is building a pipeline of MCM therapies. It has also appointed George Golumbeski as Chairman and entered a strategic collaboration with 3SBio to commercialize select MCM antibodies in Greater China while retaining global rights.

Led · Series B · May 2018

Refuge Biotechnologies develops intelligent cell therapeutics engineered to make decisions inside patients using its receptor‑dCas platform, which employs a mutated or dead Cas9 (dCas) to enable precision CRISPR activation and interference. The company is led by co‑founder and CEO Bing C. Wang, Ph.D., with Francesco Marincola, M.D., newly appointed as chief scientific officer. Refuge intends to use the financing to advance cell therapies built on its receptor‑dCas platform and to support collaborative research with partners. As part of the financing, lead investors will have an exclusive right to negotiate development and commercialization rights for therapies using the platform in China. Refuge and 3SBio will collaborate on research to develop programmed cell therapeutics that can produce therapeutic proteins inside a patient’s body. The company is based in Menlo Park, California.